newsfilter

Outlook of Nov 11, 2026. Latest Drug Manufacturers - General outlook →

Drug Manufacturers - General — industry outlook

  • Period: 2026-10-21 to 2026-11-11
  • Events: 4
  • Generated: 2026-11-11T07:30:00.005Z

Financial Guidance and Volume Growth

Bristol Myers Squibb (BMY) and Eli Lilly (LLY) both raised full-year 2026 guidance driven by strong third-quarter performance, though they face different margin dynamics. BMY raised its 2026 Non-GAAP EPS guidance to $6.35–$6.55 (excluding $0.58/share of one-time charges), while LLY raised 2026 Non-GAAP EPS to $35–$36 and revenue to $91–$92 billion (an increase of roughly $10 billion over initial guidance). LLY expects its 2026 Non-GAAP operating margin to be 52%–52.5%, noting that one-time items including $2 billion in milestone payments and a $410 million Beringer Ingelheim payment skewed the current revenue figure. Both companies anticipate significant growth in their respective flagship portfolios, with BMY projecting legacy revenue decline of 3%–5% and LLY projecting sustained volume growth in the incretin market with 82% U.S. prescription growth in Q3. BMY anticipates a $1.5–$2 billion revenue step-down in 2027 due to Loss of Exclusivity (LOE), whereas LLY expects 2027 pricing to face headwinds from a mix shift toward lower net prices in Medicare/Medicaid, despite stable commercial pricing.

Pipeline Milestones and Launch Timelines

Multiple companies outlined specific data readout and regulatory targets for the 2026–2027 period. BMY expects Phase 3 data for Admilpirant in Progressive Pulmonary Fibrosis (PPF) in Q1 2027 and Milvexian data for Secondary Stroke Prevention before year-end 2026, with Atrial Fibrillation data expected in Q1 2027. The company targets a PDUFA date of May 13, 2027, for Mezignamide and Phase 3 readouts for SOTIC2 (Lupus) before year-end 2026. LLY anticipates launching Fondeo for type 2 diabetes in the U.S. in Q4 2026, with a global rollout in 2027, and expects Ember-4 trial readouts in 2027. Additionally, BMY's ZemBexis (Cell Mod) is anticipated to become a foundational therapy alongside Mezignamide, while LLY plans to submit data for Leverkizumab for hand/foot atopic dermatitis. In contrast, BMY paused its ZolaCell autoimmune program due to a safety signal, awaiting regulatory discussions to restart, whereas LLY continues advancing its neuroscience pipeline with Kisunla and the Trailblazer-3 prevention trial.

Capital Allocation, Manufacturing, and R&D Efficiency

Major manufacturers are committing significant capital to expand capacity and improve operational efficiency. BMY announced a $2.3 billion investment for a new manufacturing campus in Houston and a > $170 million investment for a radiopharmaceutical facility in Indiana by end of 2029, aiming for $2 billion in efficiency savings by end of 2027. BMY also targets 20–30% reduction in drug testing timelines through AI integration with partners like Anthropic and NVIDIA. LLY is investing $11.5 billion total across two new facilities in Houston ($6.5B) and Richmond, VA ($5B) to support long-term growth, while aiming to provide obesity treatment to resource-limited settings by 2040. Smaller biotech Medicus Pharma (MDCX) is restructuring to be "capital-efficient," allocating $3 million over the next two years for the SkinJet 005 study and NDA preparation, while pursuing a SPAC transaction for SkinJet at a $135 million pre-money valuation in the first half of 2027.

Competitive Landscape and Therapeutic Market Dynamics

The industry is characterized by aggressive expansion into obesity and precision oncology, with specific market share and competitive benchmarks highlighted. LLY reports holding >60% of the U.S. Type 2 Diabetes incretin market and ~58% of the international market, with its oral candidate Fondeo capturing ~45% of new oral GLP-1 growth in Q3. BMY is shifting Multiple Myeloma treatment toward cell mods and CAR-T (Arlocell, ZemBexis, Mezignamide), aiming to replace Revlimid-based regimens, while anticipating the IPF/PPF market to nearly double to a $4 billion opportunity by replacing older therapies. BMY notes a potential market of 7 million patients in the U.S. for Alzheimer's Disease Psychosis (CoBenfi) and estimates 18,000 annual GEPNET diagnoses in the U.S. for its radiopharmaceutical RAISE-101. LLY highlights Retatrutide's potential for 20–21% weight loss versus 9.4% for semaglutide, while BMY tracks the conversion of Opdivo to Cuvantic, targeting 30%–40% conversion of IV business by the end of the launch phase.

Strategic Risks and Execution Uncertainties

Significant risks loom over the outlooks, ranging from pricing headwinds to clinical setbacks. BMY faces a projected $1.5–$2 billion revenue decline in 2027 from Eliquis LOE and navigates the safety pause of ZolaCell. LLY anticipates net realized price declines in the U.S. due to the Medicare GLP-1 Bridge Program, though management expects the program to be fully integrated into Part D by 2028. BMY's Admilpirant faces mixed dose results at 120mg in IPF, and LLY's Fondeo launch relies on successful regulatory review in Q4 2026. MDCX faces the risk that its SkinJet SPAC transaction may not close within the first half of 2027 and that its CD228V trial may fail to meet the >30% objective response rate target in melanoma. BMY also notes inventory drawdown impacts normalizing in Q4 2026, while LLY warns of supply chain constraints that could limit growth if demand exceeds current capacity.